TODO: Skip to main content
Top
Gepubliceerd in:

01-08-2012 | Original paper

Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes

Auteurs: Beth Malow, Karen W. Adkins, Susan G. McGrew, Lily Wang, Suzanne E. Goldman, Diane Fawkes, Courtney Burnette

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 8/2012

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Supplemental melatonin has shown promise in treating sleep onset insomnia in children with autism spectrum disorders (ASD). Twenty-four children, free of psychotropic medications, completed an open-label dose-escalation study to assess dose–response, tolerability, safety, feasibility of collecting actigraphy data, and ability of outcome measures to detect change during a 14-week intervention. Supplemental melatonin improved sleep latency, as measured by actigraphy, in most children at 1 or 3 mg dosages. It was effective in week 1 of treatment, maintained effects over several months, was well tolerated and safe, and showed improvement in sleep, behavior, and parenting stress. Our findings contribute to the growing literature on supplemental melatonin for insomnia in ASD and inform planning for a large randomized trial in this population.
Literatuur
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.
Metagegevens
Titel
Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes
Auteurs
Beth Malow
Karen W. Adkins
Susan G. McGrew
Lily Wang
Suzanne E. Goldman
Diane Fawkes
Courtney Burnette
Publicatiedatum
01-08-2012
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 8/2012
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-011-1418-3